Jan 8 (Reuters) - MOLECULAR PARTNERS AG:
* REPORTS PROMISING INITIAL SAFETY AND EFFICACY DATA FROM ITS ONGOING PHASE 2 STUDY OF MP0250 IN MULTIPLE MYELOMA
* ADDITIONAL SAFETY AND EFFICACY DATA ARE EXPECTED BY END OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 